Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease

Neurology

Volumn 72, Issue 17, 2009, Pages 1487-1494

  Drzezga, A ^a   Grimmer, T ^b   Henriksen, G ^a   Muhlau M ^b   Perneczky, R ^b   Miederer, I ^a   Praus, C ^a   Sorg, C ^b   Wohlschlager A ^a,b   Riemenschneider, M ^b   Wester, H J ^a   Foerstl, H ^b   Schwaiger, M ^a   Kurz, A ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CARBON 11; APOLIPOPROTEIN E4; BENZOTHIAZOLE DERIVATIVE; CARBON; DIAGNOSTIC AGENT; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE;

ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENOTYPE; GRAY MATTER; HUMAN; IN VIVO STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; AGED; BRAIN; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MALE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; RISK FACTOR; SCINTISCANNING; SENILE PLAQUE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BENZOTHIAZOLES; BRAIN; CARBON RADIOISOTOPES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS; SENILE PLAQUES;

EID: 67549147148     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a2e8d0     Document Type: Article

References (40)

1. Bennett DA, Wilson RS, Schneider JA, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 2003; 60:246-252.
2. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-1247.
3. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med 2007;11:1227-1238.
4. Beffert U, Cohn JS, Petit-Turcotte C, et al. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are diseaserelated and apolipoprotein E genotype dependent. Brain Res 1999;843:87-94.
5. Roses AD. Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis 1997;4: 170-185.
6. Esler WP, Marshall JR, Stimson ER, et al. Apolipoprotein E affects amyloid formation but not amyloid growth in vitro: mechanistic implications for apoE4 enhanced amyloid burden and risk for Alzheimer's disease. Amyloid 2002;9:1-12.
7. Arendt T, Schindler C, Bruckner MK, et al. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci 1997;17:516-529.
8. Reiman EM, Chen K, Caselli RJ, et al. Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. Neuroimage 2008;40: 1214-1221.
9. Burggren AC, Zeineh MM, Ekstrom AD, et al. Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage 2008;41:1177-1183.
10. Chen K, Reiman EM, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry 2007;164:916-921.
11. Shaw P, Lerch JP, Pruessner JC, et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol 2007;6:494-500.
12. Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005;46:1625-1632.
13. Hamalainen A, Grau-Olivares M, Tervo S, et al. Apolipoprotein E epsilon 4 allele is associated with increased atrophy in progressive mild cognitive impairment: a voxelbased morphometric study. Neurodegen Dis 2008;5:186- 189.
14. Drzezga A, Riemenschneider M, Strassner B, et al. Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 2005;64:102-107.
15. Hirono N, Hashimoto M, Yasuda M, et al. The effect of APOE epsilon4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology 2002;58:743- 750.
16. Barber R, Gholkar A, Scheltens P, et al. Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol 1999;56:961- 965.
17. Hashimoto M, Yasuda M, Tanimukai S, et al. Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 2001;57:1461-1466.
18. Mori E, Lee K, Yasuda M, et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol 2002;51:209-214.
19. Yasuda M, Mori E, Kitagaki H, et al. Apolipoprotein E epsilon 4 allele and whole brain atrophy in late-onset Alzheimer's disease. Am J Psychiatry 1998;155:779-784.
20. Drzezga A, Grimmer T, Henriksen G, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 2008;39:619-633.
21. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.
22. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004;3:519-527.
23. Rowe CC, Ng S, Ackermann U, et al. Imaging betaamyloid burden in aging and dementia. Neurology 2007; 68:1718-1725.
24. Ziolko SK, Weissfeld LA, Klunk WE, et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 2006;33:94-102.
25. Jack CR Jr, Lowe VJ, Senjem ML, et al. [11]C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-680.
26. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002;15:870-878.
27. Martin AJ, Friston KJ, Colebatch JG, Frackowiak RS. Decreases in regional cerebral blood flow with normal aging. J Cereb Blood Flow Metab 1991;11:684-689.
28. Akanuma N, Reed LJ, Marsden PK, et al. Hemispherespecific episodic memory networks in the human brain: a correlation study between intracarotid amobarbital test and [(18)F]FDG-PET. J Cogn Neurosci 2009;21:605- 622.
29. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
30. Mielke R, Zerres K, Uhlhaas S, Kessler J, Heiss WD. Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease. Neurosci Lett 1998; 254:49-52.
31. Baron JC, Chetelat G, Desgranges B, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage 2001;14:298-309.
32. Josephs KA, Whitwell JL, Ahmed Z, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 2008;63:204-212.
33. Ashford JW. APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol Neurosci 2004;23: 157-165.
34. Lambert JC, Mann D, Richard F, et al. Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease? J Neurol Neurosurg Psychiatry 2005;76: 928-933.
35. Ohm TG, Scharnagl H, Marz W, Bohl J. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol 1999;98:273-280.
36. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-335.
37. Grimmer T, Henriksen G, Wester HJ, et al. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging Epub 2008 Mar 18.
38. Lockhart A, Lamb JR, Osredkar T, et al. PIB is a nonspecific imaging marker of amyloid-beta (Abeta) peptiderelated cerebral amyloidosis. Brain 2007;130:2607-2615.
39. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004;62:1977-1983.
40. Grundman M, Black R. Clinical trials of bapineuzumab a beta-amyloid-targeted immunotherapy in patients with mild-to-moderate Alzheimer's disease. In: International Conference on Alzheimer's Disease (ICAD) 2008. Chicago: 2008.